Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm
NCT ID: NCT01111110
Last Updated: 2022-02-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
88 participants
INTERVENTIONAL
2008-05-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes
NCT01323010
Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children
NCT00144846
Treatment of Persistent Wheezing in Infants and Children
NCT00301171
Comparing the Efficacy of Two Valved Holding Chambers in Acute Wheezing
NCT03900494
HFCWO in Hospitalized Asthmatic Children
NCT00722020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-static then Static for Albuterol
albuterol anti-static first then static chamber second.
anti-static then static
Albuterol using static chambers
Static then Anti-static for Albuterol
static then antistatic albuterol
Static then anti-static chamber
albuterol with Static then anti-static chambers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anti-static then static
Albuterol using static chambers
Static then anti-static chamber
albuterol with Static then anti-static chambers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physician diagnosis of asthma.
* FEV1 60-80% predicted during the day.
* FEV1 increases ≥ 12 % and to ≥ 80% predicted after 2- 4 puffs of albuterol HFA MDI delivered by antistatic VHC.
* No smoking in the previous year and \< 10-pack year history.
* No history of severe asthma attacks requiring ER visit or hospitalization in the previous three months.
Exclusion Criteria
* Any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications.
* History of viral respiratory tract infection in the 3 weeks prior to the screening visit.
* Positive pregnancy test.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Miracle Network
OTHER
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Children's Miracle Network UFl
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
IRB 103-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.